UCB, ImClone to jointly develop anti-tumor antibody

UCB and ImClone Systems have joined forces to develop CDP-791, an antibody targeting blood-vessel growth in tumors that recently passed Phase I trials. A Phase II study of the treatment is set to begin within weeks. The agreement calls for UCB and ImClone to share development costs -- and eventual profits -- equally. "This is an important milestone in the building of UCB's oncology franchise," stated Melanie Lee, executive vice president R&D for UCB.

- read this press release for more

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.